Screener
Janux Therapeutics JANX Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Janux Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The source filing: Janux Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:18 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338078
| Assets | June 30,2026 / (unaudited) | December 31,2025 |
|---|---|---|
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $3,017 | $4,971 |
| Accrued expenses | 19,513 | 17,633 |
| Current portion of deferred revenue | 35,070 | — |
| Current portion of operating lease liabilities | 2,552 | 2,393 |
| Total current liabilities | 60,152 | 24,997 |
| Deferred revenue, net of current portion | 1,079 | — |
Item 1. Financial Statements.
FAQ
- What is Janux Therapeutics's accrued expenses?
- Janux Therapeutics (JANX) reported accrued expenses of $19.51M in Q2 2026.
- How has Janux Therapeutics's accrued expenses changed year-over-year?
- Janux Therapeutics's accrued expenses increased by 21.7% year-over-year, from $16.03M to $19.51M.
- What is the long-term trend for Janux Therapeutics's accrued expenses?
- Over 5 years (2020 to 2025), Janux Therapeutics's accrued expenses has grown at a 88.0% compound annual growth rate (CAGR), from $751K to $17.63M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Janux Therapeutics's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude